New data from two phase 3 studies found that in patients with relapsing forms of multiple sclerosis (MS), the new anti-CD20 monoclonal antibody drug, ublituximab, is associated with significant ...
INDIANAPOLIS -- Daclizumab HYP (Zinbryta) may have an advantage over interferon-beta-1a (Avonex) in terms of patient-centered functional outcomes in multiple sclerosis (MS), researchers reported here.
The Multiple Sclerosis Functional Composite (MSFC) score is a brief measure of functional capacity that examines ambulation, upper extremity function, and cognitive function with one validated test of ...
Data presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, HI JERUSALEM, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today ...
SALT LAKE CITY, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical ...
Understanding the neurodegenerative processes involved in MS, particularly the role of white matter (WM) and grey matter (GM), may help clinicians to diagnose the disease earlier and maximize ...
EDMONTON, Jan. 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results ...
- Data shows 78 percent of patients treated with alemtuzumab remained relapse-free for two years compared with patients on high dose IFNβ-1a - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results